Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Nihon Pharmaceutical

Next Previous
Drug Profile

Immune globulin - Nihon Pharmaceutical

Alternative Names: Dried polyethylene glycol-treated human immunoglobulin - Nihon Pharmaceutical; GLOVENIN-I; Immunoglobulin intravenous - Nihon Pharmaceutical; Kenketu Glovenin-I; Kenketu Glovenin-I-Nichiyaku; NPB-01; TAK-961

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nihon Pharmaceutical
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Agammaglobulinaemia; Bullous pemphigoid; Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Motor neuron disease; Pemphigus; Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • Phase III Encephalitis
  • Phase II Neuromyelitis optica

Most Recent Events

  • 28 Aug 2024 Takeda plans to file regulatory applications for multiple indications in Japan, in 2024 (Takeda pipeline, August 2024)
  • 03 Mar 2022 Phase-III clinical trials in Encephalitis (Treatment-resistant) in Japan (IV) (NCT05177939)
  • 05 Jan 2022 Nihon Pharmaceutical plans a phase III trial for autoimmune Encephalitis (In adolescents, In adults, In the elderly, Treatment-experienced) (IV), in February 2022 (NCT05177939)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top